CanBas Co

CanBas Co Receivables/Revenue

The Receivables to Revenue Ratio of CanBas Co (4575.T) as of Nov 18, 2026 is 50.96 %. In the previous year, Receivables to Revenue Ratio was 53.17 % — a change of -4.17% (lower).

Receivables/Revenue

50.96 %

YoY

-4.17%

Last updated:

Receivables to Revenue Ratio of CanBas Co is 2020 50.96 % . Receivables to Revenue Ratio of CanBas Co was 2019 53.17 % . It decreases by -4.17% lower compared to the previous year.

The CanBas Co Receivables/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables/Revenue
Date
Receivables/Revenue
Jan 1, 2015
83.60 JPY
Jan 1, 2016
53.40 JPY
Jan 1, 2017
51.03 JPY
Jan 1, 2018
50.96 JPY
Jan 1, 2019
53.17 JPY
Jan 1, 2020
50.96 JPY
The CanBas Co Receivables/Revenue history
YEARReceivables/RevenueYoY
50.96 %-4.17%
53.17 %+4.35%
50.96 %-0.13%
51.03 %-4.45%
53.40 %-36.12%
83.60 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CanBas Co Stock analysis

What does CanBas Co do? CanBas Co., Ltd. generates revenue through pharmaceutical research and development, focusing on basic anticancer drug discovery and early clinical development. The company develops drug discovery concepts, selects candidate compounds, conducts simple animal studies, and analyzes basic data on anticancer drug candidates entering development. It also performs preclinical studies for clinical trial applications and manages the initial phase of clinical trials. The primary buyers of these services are pharmaceutical companies seeking to advance their anticancer drug pipelines through early-stage research and development. CanBas Co., Ltd. operates with a team of 12 full-time employees, specializing in anticancer drug research. The company's services are tailored for pharmaceutical firms requiring expertise in early-stage drug development, particularly in the discovery and preclinical phases. Its focus on basic anticancer drug research and early clinical development positions it as a specialized provider in the pharmaceutical R&D sector. The firm's business model relies on providing comprehensive research services to pharmaceutical companies, including concept development, compound selection, animal studies, and data analysis. These services are critical for pharmaceutical firms to progress anticancer drug candidates from discovery to early clinical stages, ensuring efficient and effective development pathways for new treatments. CanBas Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CanBas Co stock

Receivables to Revenue Ratio of CanBas Co is 50.96 % in 2020.

Receivables to Revenue Ratio of CanBas Co changed from 53.17 % to 50.96 %, representing a -4.17% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Receivables to Revenue Ratio CanBas Co since 2006 – with annual values, charts, and detailed analysis.

The Receivables/Revenue ratio shows what percentage of annual revenue is tied up in accounts receivable. Rising ratios may signal collection issues.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Receivables to Revenue Ratio's CanBas Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Receivables to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Receivables to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — CanBas Co

All Key Metrics — CanBas Co